Carolina Álvarez-Delgado

Carolina Álvarez-Delgado

Auto-generated profile, based on publicly available information

Carolina Álvarez-Delgado

Universidad Politécnica de Sinaloa

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in European Journal of Pharmacology
Verified
Journal Article
Closed access
AMAldo Moreno-Ulloa
Aldo Moreno-Ulloa
AMAdriana Miranda-Cervantes
Adriana Miranda-Cervantes
Alexei Fedorovish Licea-NavarroAlexei Fedorovish Licea-Navarro
Alexei Fedorovish Licea-Navarro
CMChristina Mansour
Christina Mansour
EBErnesto Beltrán-Partida
Ernesto Beltrán-Partida
CÁCarolina Álvarez-Delgado
Carolina Álvarez-Delgado

2 June 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
CVClaudia Ventura-López
Claudia Ventura-López
KCKarla Cervantes-Luevano
Karla Cervantes-Luevano
JAJanet S. Aguirre-Sánchez
Janet S. Aguirre-Sánchez
JFJuan C. Flores-Caballero
Juan C. Flores-Caballero
CACarolina Alvarez-Delgado
Carolina Alvarez-Delgado
Alexei Fedorovish Licea-NavarroAlexei Fedorovish Licea-Navarro
Alexei Fedorovish Licea-Navarro
The health crisis caused by the new coronavirus SARS-CoV-2 highlights the need to identify new treatment strategies for this viral infection. During the past year, over 400 coronavirus disease (COVID-19) treatment patents have been registered; nevertheless, the presence of new virus variants has triggered more severe disease presentations and reduced treatment effectiveness, highlighting the need for new treatment options for the COVID-19. This study evaluates the Metformin Glycinate (MG) effect on the SARS-CoV-2 in vitro and in vivo viral load. The in vitro study was conducted in a model of Vero E6 cells, while the in vivo study was an adaptive, two-armed, randomized, prospective, longitudinal, double-blind, multicentric, and phase IIb clinical trial. Our in vitro results revealed that MG effectively inhibits viral replication after 48 h of exposure to the drug, with no cytotoxic effect in doses up to 100 µM. The effect of the MG was also tested against three variants of interest (alpha, delta, and epsilon), showing increased survival rates in cells treated with MG. These results are aligned with our clinical data, which indicates that MG treatment reduces SARS-CoV2-infected patients´ viral load in just 3.3 days and supplementary oxygen requirements compared with the control group. We expect our results can guide efforts to position MG as a therapeutic option for COVID-19 patients.

1 October 2012 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
NPNatalia Pavón Pavón
Natalia Pavón Pavón
EMEduardo Martínez-Abundis
Eduardo Martínez-Abundis
LHLuz Hernández
Luz Hernández
JGJuan Carlos Gallardo-Pérez
Juan Carlos Gallardo-Pérez
CACarolina Alvarez-Delgado
Carolina Alvarez-Delgado
ECEdmundo Chávez
Edmundo Chávez

1 August 2010 in Experimental Gerontology
Verified
Journal Article
Closed access
CÁCarolina Álvarez-Delgado
Carolina Álvarez-Delgado
CMC. Adriana Mendoza-Rodríguez
C. Adriana Mendoza-Rodríguez
OPOfir Picazo
Ofir Picazo
MCMarco Cerbón
Marco Cerbón

5 February 2016 in Toxins
Verified
Journal Article
Open access
PDF file
IOIrasema Oroz
Irasema Oroz
MNMario Navarro
Mario Navarro
KCKarla Cervantes
Karla Cervantes
CÁCarolina Álvarez-Delgado
Carolina Álvarez-Delgado
GSGuy Salvesen
Guy Salvesen
Alexei Fedorovish Licea-NavarroAlexei Fedorovish Licea-Navarro
Alexei Fedorovish Licea-Navarro
Lung cancer is one of the most common types of cancer in men and women and a leading cause of death worldwide resulting in more than one million deaths per year. The venom of marine snails Conus contains up to 200 pharmacologically active compounds that target several receptors in the cell membrane. Due to their diversity and specific binding properties, Conus toxins hold great potential as source of new drugs against cancer. We analyzed the cytotoxic effect of a 17-amino acid synthetic peptide (s-cal14.1a) that is based on a native toxin (cal14.1a) isolated from the sea snail Conus californicus. Cytotoxicity studies in four lung cancer cell lines were complemented with measurement of gene expression of apoptosis-related proteins Bcl-2, BAX and the pro-survival proteins NFκB-1 and COX-2, as well as quantification of caspase activity. Our results showed that H1299 and H1437 cell lines treated with s-call4.1a had decreased cell viability, activated caspases, and reduced expression of the pro-survival protein NFκB-1. To our knowledge, this is the first report describing activation of apoptosis in human lung cancer cell lines by s-cal14.1a and we offer insight into the possible mechanism of action.

25 April 2022 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
CÁCarolina Álvarez-Delgado
Carolina Álvarez-Delgado